B12 Is Not One Molecule: Methylcobalamin vs Cyanocobalamin vs Hydroxocobalamin vs Adenosylcobalamin, and Why "Active B12" on the Label Is Only Half the Story

Pull four B12 supplements off the same shelf. The first says "Vitamin B12 (as cyanocobalamin) 1,000 mcg." The second says "Methylcobalamin (Active B12) 5,000 mcg." The third says "B12 Complex — methylcobalamin + adenosylcobalamin 2,500 mcg." The fourth — a specialty product with a higher price tag — says "Hydroxocobalamin 1,000 mcg." All four are labeled Vitamin B12. None of the four labels tells the buyer whether the form in the bottle matches the situation of the person taking it.

B12 is not a single molecule. Cobalamin is a family of related corrinoid compounds built around a cobalt-containing corrin ring, differing at the upper axial ligand attached to the cobalt atom. The four ligand variants that show up on retail labels — cyano, methyl, hydroxo, and adenosyl — have different manufacturing sources, different in-vivo conversion requirements, different retention profiles, and different relevance depending on who is taking them and why. The "active B12" marketing frame that has taken over the category compresses all of that into a single label claim that does not survive contact with the actual biochemistry.

This post is the form-and-dose read on the four common cobalamins: what each form actually is, the intrinsic-factor absorption ceiling that caps oral B12 absorption in physiological doses and the passive-diffusion pathway that lets megadoses partially bypass it, the "active B12" claim and what the trial literature does and does not support, the sublingual-versus-oral question that the pharmacokinetic evidence has mostly answered, and the label patterns that separate a serious B12 product from a marketing product.

The Four Forms

Cyanocobalamin is the synthetic, cyanide-adducted form used in most fortified foods, most multivitamins, and the majority of standalone B12 supplements at the mass-market end. It does not exist in nature in meaningful amounts. Cyanocobalamin is chemically stable, cheap to manufacture, and has been the workhorse form of B12 supplementation and B12 injection therapy for most of a century. The cyanide ligand is released during intracellular conversion — the amount of cyanide liberated from a 1,000 mcg cyanocobalamin dose is trivial (about 20 mcg) relative to the amounts of cyanide the healthy liver processes daily from other sources. Cyanocobalamin has to be converted intracellularly to the two active coenzyme forms — methylcobalamin (used by methionine synthase in the cytoplasm) and adenosylcobalamin (used by methylmalonyl-CoA mutase in the mitochondria) — before it can serve as a coenzyme.

Methylcobalamin is one of the two active coenzyme forms. Methionine synthase uses methylcobalamin to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine. This is the reaction at the intersection of the folate cycle and the methionine cycle — the reaction that connects B12 status to homocysteine, and by extension to the cardiovascular and neurological endpoints B12 deficiency threatens. Supplemental methylcobalamin does not require the initial conversion step, though it does still require the intracellular retention and re-methylation that any B12 form eventually undergoes.

Adenosylcobalamin (also called dibencozide or coenzyme B12) is the other active coenzyme form. Methylmalonyl-CoA mutase uses adenosylcobalamin to catalyze the isomerization of methylmalonyl-CoA to succinyl-CoA in the mitochondria. This is the reaction whose upstream substrate — methylmalonic acid (MMA) — is the clinical biomarker most sensitive to functional B12 deficiency. Adenosylcobalamin is less common on retail labels than methylcobalamin, usually appearing in "B12 complex" products marketed on the "both active forms" claim.

Hydroxocobalamin is the natural precursor form to the two active coenzyme cobalamins, produced by bacteria and found in some animal-source foods. In pharmaceutical use, hydroxocobalamin is the form used for intramuscular injection in most European clinical settings (cyanocobalamin is more common for injection in North America), and it is the antidote form used in cyanide poisoning at gram-scale doses. Hydroxocobalamin has a longer serum half-life and a longer retention time than cyanocobalamin after injection, which is why it can be dosed less frequently in maintenance IM protocols. In oral supplementation, hydroxocobalamin is less common on retail shelves but appears in some specialty products.

The four forms are not interchangeable in every situation. For a healthy adult with normal intrinsic-factor secretion supplementing prophylactically, any of the four forms will work — the body has the machinery to convert cyanocobalamin or hydroxocobalamin to the active coenzyme forms as needed. For specific clinical situations — deep deficiency workups, symptomatic neuropathy on a maintenance oral protocol, patients with rare inborn errors of cobalamin metabolism — the form question matters more, and the answer is often case-specific rather than "always methylcobalamin."

The Intrinsic-Factor Absorption Ceiling

Physiological B12 absorption is a two-step gastric-and-ileal process. B12 in food or supplements binds to a stomach-produced glycoprotein called intrinsic factor. The B12-intrinsic-factor complex is absorbed at receptors specifically located in the terminal ileum. The system is transporter-limited: the intrinsic-factor-mediated absorption ceiling is approximately 1.5 to 2 mcg per meal or dose, regardless of how much B12 is presented to the gut.

This means that a 1,000 mcg cyanocobalamin oral supplement does not deliver 1,000 mcg of absorbed B12 through the intrinsic-factor pathway. It delivers approximately 1.5 to 2 mcg through that pathway — the same as a 5 mcg supplement or a 25 mcg supplement would deliver — because the ceiling is fixed at the transporter level.

The reason megadose oral B12 works at all is a second, separate absorption pathway: passive diffusion. Roughly 1 to 2 percent of an oral B12 dose is absorbed passively across the intestinal mucosa, without intrinsic factor and without saturable transporters. For a 1,000 mcg dose, the passive-diffusion contribution is roughly 10 to 20 mcg — an order of magnitude greater than what the intrinsic-factor pathway can deliver from any single meal. This is the mechanism by which oral B12 megadoses can be used to treat pernicious anemia (the classic intrinsic-factor-deficient condition), and this is the mechanism by which the standard 500 to 1,000 mcg B12 supplement gets meaningful B12 into circulation even in older adults with reduced intrinsic-factor secretion.

The practical implications:

• The RDA is 2.4 mcg per day. That number was set on the assumption of a functional intrinsic-factor pathway plus a background of dietary B12. It is not the "supplement dose to buy" — it is the estimated daily requirement to reach tissue adequacy.
• A 100 mcg supplement is enough for a healthy adult without absorption issues. The intrinsic-factor pathway plus a small passive-diffusion contribution will comfortably cover the daily requirement.
• A 500 to 1,000 mcg supplement is a reasonable middle ground for older adults with mild absorption reduction, for strict plant-based eaters with no dietary B12, and for adults whose homocysteine or MMA screening has come back at the upper end of the range without a clear deficiency picture yet.
• A 5,000 mcg (or higher) supplement is the megadose window — appropriate for documented deficiency treatment protocols, for patients with pernicious anemia on an oral rather than injection regimen, and for the "high-dose to overcome absorption limits" strategy used in some clinical settings. The higher dose does not proportionally raise blood B12 — the diffusion pathway is roughly linear in this range but the returns diminish as you climb.

The label that markets "5,000 mcg for maximum absorption" without the intrinsic-factor context is exploiting the buyer's assumption that "more mcg = more absorbed." The absorption ceiling caps most of the dose regardless of the marketing claim.

The "Active B12" Claim and What the Trial Literature Actually Shows

The methylcobalamin marketing case is that "active B12" bypasses a conversion bottleneck and is therefore superior for people with poor conversion capacity — often invoked alongside the MTHFR polymorphism discussion.

The trial literature is more nuanced than the marketing case.

Cyanocobalamin is converted to methylcobalamin and adenosylcobalamin efficiently in healthy adults. The conversion is not a bottleneck comparable to the folate cycle's MTHFR step. Trials that have compared serum B12 and holotranscobalamin (the active-transport form) response between oral cyanocobalamin and methylcobalamin in healthy adults show broadly similar responses when doses are matched.

Retention differs. Some studies show slightly higher urinary excretion of cyanocobalamin than methylcobalamin at matched doses, suggesting the active forms are retained somewhat more efficiently at the tissue level. The clinical significance of that difference for healthy supplementation is small.

In specific clinical situations, methylcobalamin has a plausible edge. Case series and small trials in diabetic neuropathy, some presentations of B12-responsive optic neuropathy, and a subset of pediatric inborn-error contexts have shown a preference for the active coenzyme forms. These are specialist decisions made in clinical settings, not the general case for retail supplementation.

The MTHFR-argument for methylcobalamin over cyanocobalamin overreaches. MTHFR is the folate-cycle enzyme, not a cobalamin-cycle enzyme. MTHFR polymorphisms affect the availability of 5-methyltetrahydrofolate, which is the methyl-group donor at the methionine-synthase step. The argument that MTHFR-variant individuals should preferentially take methylcobalamin extrapolates from the folate-form debate rather than reflecting the cobalamin conversion mechanism directly. There is a case for methylcobalamin in some contexts — the case just is not "because MTHFR."

For the healthy adult buying a B12 supplement without a specific clinical indication, the "active B12 vs regular B12" decision is a smaller variable than the dose and adherence variables. A 500 mcg cyanocobalamin taken daily is more useful than a 5,000 mcg methylcobalamin taken sporadically.

The Sublingual vs Oral Question

The sublingual-B12 marketing claim is that oral-mucosa absorption bypasses gastric and ileal issues and delivers higher bioavailability. The pharmacokinetic evidence is more limited than the marketing claim.

Multiple studies comparing serum B12 response between sublingual and oral cobalamin — at matched doses in similar populations — have found no meaningful difference in serum B12 or holotranscobalamin response. The proposed sublingual-absorption mechanism appears to contribute a small fraction of total delivered B12; most of a sublingual lozenge or tablet is ultimately swallowed and absorbed by the same intestinal pathways as a conventional oral form.

That said, sublingual delivery has one legitimate use case: it removes the swallowing requirement and can be helpful for patients with dysphagia or medication-adherence issues. As a bioavailability improvement over conventional oral, the evidence does not support the price premium most sublingual products carry.

The buyer decision: choose an oral or sublingual delivery form based on personal preference and adherence, not on a bioavailability claim.

Absorption-Compromising Situations to Screen For

Several conditions and medications reduce B12 absorption through the intrinsic-factor pathway and shift the supplementation calculus:

• Pernicious anemia (autoimmune destruction of intrinsic-factor-producing parietal cells): the classic B12-absorption failure that historically required IM injection but can often be managed with high-dose oral supplementation working through the passive-diffusion pathway.
• Chronic proton-pump inhibitor use (omeprazole and family, more than 12 months of continuous use): reduces the gastric-acid step needed to release protein-bound dietary B12, meaningfully reduces the food-B12 absorption fraction, minimally affects supplemental crystalline B12 absorption.
• Chronic metformin use: reduces B12 absorption through a calcium-dependent mechanism at the ileal receptor; the effect accumulates over years and can produce measurable deficiency even in the absence of overt symptoms. Long-term metformin patients should have B12 status monitored periodically.
• Bariatric surgery — especially Roux-en-Y and biliopancreatic diversion — anatomically bypasses the terminal ileum and requires lifelong high-dose oral or IM supplementation.
• Autoimmune atrophic gastritis (Type A), Zollinger-Ellison syndrome, ileal Crohn's disease, and prior ileal resection all disrupt the intrinsic-factor or ileal-absorption steps.

The screening implication for a supplement buyer: if you are on chronic PPI or metformin, or if you have had bariatric surgery, your B12 supplementation strategy should be informed by periodic status monitoring (serum B12 plus MMA and homocysteine if the serum value is ambiguous) rather than by guessing at a "reasonable dose."

Label Patterns That Separate Real from Marketing

The label pattern that indicates a serious B12 product:

• Form disclosed explicitly. "Vitamin B12 (as methylcobalamin) 1,000 mcg" or "Vitamin B12 (as cyanocobalamin) 1,000 mcg." A label that says "Vitamin B12 1,000 mcg" without the parenthetical form disclosure has not told the buyer what molecule is in the bottle.
• Single dose per serving with the form matched to the intended use. For general supplementation, cyanocobalamin or methylcobalamin at 500 to 1,000 mcg is defensible. For older-adult supplementation or documented low-B12 status, 1,000 to 5,000 mcg with either form is defensible.
• "B12 complex" products that disclose both methylcobalamin and adenosylcobalamin doses separately. A responsible complex product tells you how much of each coenzyme form is present, not just a combined milligram total.
• Sublingual products priced comparably to oral products of the same form and dose. A sublingual product carrying a 3x price premium on a bioavailability claim that the literature does not support is a marketing product, not a science product.

The label pattern to be skeptical of:

• "Vitamin B12" with no form disclosed. The buyer has no way to evaluate the product.
• "Active B12" as a marketing claim without a molecule name attached. Sometimes this is methylcobalamin, sometimes it is a methyl-plus-adenosyl blend, sometimes it is a wrapper on standard cyanocobalamin.
• Megadose products (10,000 mcg and above) marketed with "for maximum absorption" language. The absorption pathway that responds to megadoses is passive diffusion, which is roughly linear in the megadose range but does not deliver proportional serum increases. There is no absorption advantage of 25,000 mcg over 5,000 mcg for most buyers.
• Multi-vitamin products that stack B12 with folic acid without form disclosure on either. The B12 form question and the folate form question interact — see the folate forms deep-dive — and a serious multi discloses both.

The 20-Second Label Read

Pick up the bottle. Look at the supplement-facts panel, not the front-of-label marketing.

1. Find "Vitamin B12" and read the parenthetical form. If the form is disclosed as cyanocobalamin, methylcobalamin, hydroxocobalamin, or adenosylcobalamin, you know what molecule you are buying. If the form is not disclosed, put the bottle back.
2. Read the dose in mcg. For general supplementation, 100 to 1,000 mcg is the reasonable range for most buyers. For older adults, strict plant-based eaters, or documented low status, 1,000 to 5,000 mcg is defensible. Above 5,000 mcg for general supplementation is marketing.
3. Read the delivery form. Oral tablet, capsule, or sublingual — all three deliver B12 through overlapping pathways. The delivery-form choice is preference and adherence, not bioavailability.
4. Match the form to the situation. Healthy adult prophylactic supplementation: either form works, adherence matters more than form. Older adult with reduced gastric function: cyanocobalamin or methylcobalamin at 500 to 1,000 mcg oral is defensible. Documented pernicious anemia or malabsorption: high-dose (1,000 to 5,000 mcg) oral through the passive-diffusion pathway, or IM injection under clinical supervision.

B12 is one of the cleaner supplement categories to buy well, provided the label discloses the form. The premium on "active B12" over cyanocobalamin is often not paying for a meaningful clinical advantage for the buyer who does not have a specific clinical indication that would justify it. Pay for form disclosure, appropriate dose, and a product from a manufacturer whose supplement-facts panel matches what an independent lab test would find in the bottle. Everything else is marketing.